Management of relapsed-refractory diffuse large B cell lymphoma

Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL), which accounts for approximately one-third of patients with DLBCL, remains a major cause of morbidity and mortality. Managing RR DLBCL continues to be a challenge to the treating hemato-oncologist. Salvage high-dose chemotherapy followed...

Descripción completa

Detalles Bibliográficos
Autores principales: Raut, Lalit S., Chakrabarti, Prantar P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961873/
https://www.ncbi.nlm.nih.gov/pubmed/24665451
http://dx.doi.org/10.4103/2278-330X.126531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961873/
https://www.ncbi.nlm.nih.gov/pubmed/24665451
http://dx.doi.org/10.4103/2278-330X.126531

Ejemplares similares